Veracyte to Participate in Upcoming Investor Conferences
Veracyte, Inc., a leading cancer diagnostics company, announced its participation in two upcoming investor conferences: the Raymond James 47th Annual Institutional Investors Conference on March 3rd and the Leerink Partners Global Health Conference on March 9th. The company will provide live audio webcasts of its presentations on its investor relations website, with replays available for 90 days. This press release also includes information about Veracyte's mission to transform cancer care and details about its recent financial results and upcoming earnings release.
Can OPKO Health's Pipeline Progress and Deals Drive Growth in 2026?
OPKO Health (OPK) is positioned for growth in 2026, driven by its flagship product RAYALDEE and strategic partnerships, including an expanded agreement with Entera Bio for an oral PTH analog and a collaboration with Regeneron Pharmaceuticals. The company is also advancing several clinical trials for multispecific antibodies and vaccines. Despite these growth factors, concerns remain regarding stiff competition and an overreliance on RAYALDEE for revenue.
Illinois Municipal Retirement Fund Takes Position in Veracyte, Inc. $VCYT
The Illinois Municipal Retirement Fund recently acquired a new position in Veracyte, Inc. (NASDAQ: VCYT), purchasing 40,318 shares valued at approximately $1.38 million. This move is part of broader institutional interest, with other major investors like Artisan Partners, State Street, Bank of America, and Qube Research & Technologies Limited also increasing their stakes in the biotechnology company. Despite significant insider selling over the past quarter, analysts have generally given Veracyte a "Moderate Buy" consensus rating with an average target price of $46.14.
Here's How Veracyte Stock Is Placed Ahead of Q4 Earnings
Veracyte, Inc. (VCYT) is set to announce its fourth-quarter 2025 earnings on February 25, 2026, with analysts expecting significant revenue and EPS growth compared to the prior year. The company has a strong track record of beating earnings estimates, driven by its core testing business, particularly Decipher and Afirma volumes. Veracyte also holds a Zacks Rank #2 and a positive Earnings ESP, suggesting a high probability of exceeding Q4 expectations.
Here's How Veracyte Stock Is Placed Ahead of Q4 Earnings
Veracyte, Inc. (VCYT) is set to announce its fourth-quarter 2025 results on February 25, with analysts expecting a 16.9% revenue increase and 13.9% EPS growth year-over-year. The company's core testing business, particularly Decipher and Afirma volumes, is anticipated to drive strong revenue, while its biopharmaceutical segment is expected to see a decrease due to restructuring. Vercayte currently holds a Zacks Rank #2 with a positive Earnings ESP of +7.98%, suggesting a higher chance of beating estimates.
Public Sector Pension Investment Board Invests $10.54 Million in Veracyte, Inc. $VCYT
The Public Sector Pension Investment Board has acquired a new stake of 306,918 shares in Veracyte, Inc. (NASDAQ:VCYT) during Q3, valued at approximately $10.54 million, constituting about 0.39% of the company. Veracyte currently holds a "Moderate Buy" consensus rating from brokerages with a target price of $46.14. Despite institutional buying, company insiders, including CEO Marc Stapley and Director Karin Eastham, have been net sellers in the past three months.
UBS reaffirmed buy rating on Veracyte (VCYT) after strong Q4 testing revenue
UBS has reiterated its Buy rating on Veracyte (VCYT) following impressive Q4 testing revenue, which significantly surpassed both UBS's projections and the consensus. The strong performance was attributed to a substantial beat in both ASP and volume, leading Veracyte to issue an initial 2024 top-line guidance that exceeds analyst expectations.
UBS Reaffirmed Buy Rating on Veracyte (VCYT) After Strong Q4 Testing Revenue
UBS reaffirmed its Buy rating on Veracyte (VCYT) with a $48 price target, following strong Q4 testing revenue that exceeded expectations. The company's 2026 testing revenue projections also surpassed street forecasts, and its maintained adjusted EBITDA margin of 25% for 2026 (up from 21% in 2024) was viewed favorably by the analyst. Veracyte, a genomic diagnostics company, reported preliminary Q4 2025 revenue of $138-140 million, an impressive 16%-18% year-over-year increase.
UBS Reaffirmed Buy Rating on Veracyte (VCYT) After Strong Q4 Testing Revenue
UBS reaffirmed its Buy rating for Veracyte (VCYT) with a $48 price target, following strong Q4 testing revenue that exceeded expectations. The company's 2026 testing revenue projections also beat street expectations, and its maintained adjusted EBITDA margin of 25% for 2026 (up from 21% in 2024) was viewed favorably. Veracyte is a genomic diagnostics company specializing in tests for various cancers and autoimmune diseases.
13 Best Innovative Stocks to Buy According to Wall Street Analysts
This article identifies 13 innovative stocks recommended by Wall Street analysts. It highlights Veracyte, Inc. (NASDAQ: VCYT) as an example, detailing UBS's reaffirmed Buy rating, a $48 price target, and positive commentary on its Q4 testing revenue, 2026 projections, and adjusted EBITDA margin. The company is a genomic diagnostics firm specializing in cancer and autoimmune disease tests.
13 Best Innovative Stocks to Buy According to Wall Street Analysts
Veracyte, Inc. (NASDAQ:VCYT) is highlighted as one of the best innovative stocks to buy, with a 28.38% analyst upside and 25 hedge fund holders. UBS reiterated its Buy rating with a $48 price target, following strong Q4 testing revenue that exceeded expectations due to higher average selling prices. The company's 2026 revenue projections also surpassed street expectations, and its maintained adjusted EBITDA margin of 25% (up from 21% in 2024) bodes well for its future.
Veracyte (NASDAQ:VCYT) Rating Increased to Strong-Buy at Zacks Research
Zacks Research upgraded Veracyte (NASDAQ:VCYT) from a "hold" to a "strong-buy" rating. The biotechnology company, which focuses on genomic diagnostics, has a consensus "Moderate Buy" rating and an average price target of $46.14 from analysts, though some insiders recently sold shares. Veracyte's stock opened at $35.15, trading down about 2.3%, and has a market capitalization of $2.78 billion.
56,756 Shares in Veracyte, Inc. $VCYT Bought by Thrivent Financial for Lutherans
Thrivent Financial for Lutherans has acquired a new stake of 56,756 shares in Veracyte, Inc. (NASDAQ: VCYT) during the third quarter, valued at approximately $1.95 million. This purchase represents about 0.07% of the company's stock. Despite this institutional buying, company insiders have been net sellers, offloading 68,299 shares in the last 90 days.
Veracyte, Inc. $VCYT Stock Holdings Increased by Allianz Asset Management GmbH
Allianz Asset Management GmbH increased its stake in Veracyte, Inc. (NASDAQ:VCYT) by 53.2% in Q3, now owning 134,097 shares worth approximately $4.6 million. Despite this, there has been accelerated insider selling by CFO Rebecca Chambers and Director Karin Eastham, totaling over $1.5 million in sales within a short period. Analyst ratings present a mixed view with a consensus "Hold" rating and an average price target of $46.14, although several firms issued "Buy" or "Strong-Buy" ratings while others maintained "Hold" or "Underweight."
Federated Hermes Inc. Sells 52,039 Shares of Veracyte, Inc. $VCYT
Federated Hermes Inc. significantly reduced its stake in Veracyte, Inc. by 96.1% in the third quarter, selling 52,039 shares and retaining 2,128 shares valued at $73,000. This divestment follows other institutional investors modifying their holdings, while company insiders, including the CEO and CFO, also sold a substantial number of shares recently. Despite insider and institutional selling, Wall Street analysts maintain a "Hold" consensus rating for Veracyte with a target price of $46.14.
Principal Financial Group Inc. Boosts Stake in Veracyte, Inc. $VCYT
Principal Financial Group Inc. significantly increased its stake in Veracyte, Inc. by 667.9% in the third quarter, now owning 435,761 shares valued at approximately $14.96 million. Other institutional investors also adjusted their positions, while company insiders have been net sellers, disposing of 68,299 shares worth about $3.10 million in the last 90 days. Analyst ratings for Veracyte are mixed, with an average "Hold" rating and an average target price of $46.14.
IQ EQ FUND MANAGEMENT IRELAND Ltd Has $4.78 Million Stock Holdings in Veracyte, Inc. $VCYT
IQ EQ FUND MANAGEMENT IRELAND Ltd significantly increased its stake in Veracyte, Inc. (NASDAQ:VCYT) by 97.3% in the third quarter, now owning 139,109 shares valued at $4.78 million. This move is part of a broader institutional accumulation, despite recent insider selling by Director Karin Eastham and CFO Rebecca Chambers. While Veracyte beat Q3 EPS and revenue expectations, the stock trades below recent highs and holds a consensus "Hold" rating from analysts.
Analysts Offer Insights on Healthcare Companies: Veracyte (VCYT), Sarepta Therapeutics (SRPT) and Viridian Therapeutics (VRDN)
Guggenheim reiterated a Buy rating on Veracyte (VCYT) with a $50.00 price target. Piper Sandler maintained a Hold rating on Sarepta Therapeutics (SRPT) with a $16.00 price target. Needham assigned a Buy rating to Viridian Therapeutics (VRDN) with a price target of $42.00, reflecting analyst consensus favoring a Strong Buy for VRDN.
Veracyte (VCYT) Loses 20.0% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Veracyte (VCYT) has seen a 20% decline in stock price over the past four weeks, placing it in oversold territory according to the Relative Strength Index (RSI). With an RSI of 28.44, rising earnings estimates from analysts, and a Zacks Rank #1 (Strong Buy), the company is positioned for a potential near-term trend reversal. This suggests that the stock may be undervalued due to recent selling pressure and could experience a rebound.
Veracyte to Release Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026
Veracyte, Inc. announced it will release its financial results for the fourth quarter and full-year 2025 after market close on Wednesday, February 25, 2026. The company will host a conference call and webcast on the same day at 4:30 p.m. Eastern Time to discuss the results and provide a business update, with details for webcast access and registration provided.
Veracyte to Release Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026
Veracyte, Inc. (Nasdaq: VCYT) announced it will release its financial results for the fourth quarter and full-year 2025 after the market closes on Wednesday, February 25, 2026. The company will host a conference call and webcast on the same day at 4:30 p.m. Eastern Time to discuss these results and provide a general business update. Preliminary unaudited results for Q4 and full-year 2025 indicated total revenue of between $138 million and $140 million, an increase of 16% to 18% compared to the prior year.
Veracyte, Inc. (NASDAQ:VCYT) Receives Average Rating of "Hold" from Analysts
Veracyte, Inc. (NASDAQ:VCYT) has received an average "Hold" rating from nine analysts, with a mean 12-month target price of $46.14. Despite recent insider selling, the company beat EPS and revenue estimates in its last quarterly report, with a stock price of approximately $38.16 and a market cap of $3.02 billion. Several firms have recently raised their price targets for Veracyte shares.
Improved Revenues Required Before Veracyte, Inc. (NASDAQ:VCYT) Shares Find Their Feet
Veracyte, Inc.'s low price-to-sales (P/S) ratio of 6.1x compared to the Biotech industry average suggests it might be undervalued. However, this is likely due to sluggish revenue growth and a forecast of 12% annual growth over the next three years, significantly trailing the industry's predicted 134% growth. Investors seem to be factoring in limited future growth, contributing to the reduced stock valuation.
Here's Why Veracyte (VCYT) Is a Great 'Buy the Bottom' Stock Now
Veracyte (VCYT) has shown a bearish trend recently, but a hammer chart pattern suggests a potential trend reversal. This technical indicator combined with a positive trend in earnings estimate revisions and a Zacks Rank #1 (Strong Buy) rating points to a strong possibility of upward price movement for the molecular diagnostic company. These factors make VCYT an attractive "buy the bottom" opportunity.
Veracyte, Inc. (VCYT) sees analyst support as Guggenheim reaffirms buy rating
Guggenheim has reaffirmed its Buy rating for Veracyte, Inc. (VCYT). This analyst support suggests a positive outlook for the company's stock performance.
AEGON ASSET MANAGEMENT UK Plc Has $14.06 Million Stock Position in Veracyte, Inc. $VCYT
AEGON ASSET MANAGEMENT UK Plc significantly increased its stake in Veracyte, Inc. (NASDAQ:VCYT) by 34.8% in the third quarter, now holding 409,601 shares valued at $14.06 million. The article notes mixed analyst ratings with a consensus "Hold" and a $46.14 price target, while insiders have been net sellers. Veracyte reported stronger-than-expected earnings and revenue for the last quarter.
Veracyte Inc. (NASDAQ:VCYT) Emerges as a Prime Affordable Growth Candidate
Veracyte Inc. (NASDAQ:VCYT) is presented as an "affordable growth" candidate, combining strong growth metrics with a sensible valuation within its industry. The article highlights the company's significant historical and projected sales and EPS growth, supported by a strong, debt-free balance sheet and high profit margins. It suggests VCYT offers a balance of risk and return for investors seeking growth without extreme speculation.
Stronger‑Than‑Expected Revenue Outlook Might Change The Case For Investing In Veracyte (VCYT)
Veracyte, Inc. (VCYT) recently released preliminary 2025 results and 2026 guidance, projecting higher-than-expected revenue driven by strong demand for its genomic diagnostic tests. This positive outlook supports the company's near-term growth story in precision medicine, countering recent share price underperformance. However, the article notes that Veracyte's premium valuation and execution risks related to new product launches and payer coverage remain central concerns for investors.
Stronger‑Than‑Expected Revenue Outlook Might Change The Case For Investing In Veracyte (VCYT)
Veracyte (VCYT) has released preliminary 2025 results and 2026 guidance, projecting strong revenue growth that exceeds earlier expectations. This positive outlook reinforces the company’s role in precision medicine and its near-term growth story, despite some previous share price underperformance. However, the premium valuation and execution risks associated with new product launches and payer coverage remain important considerations for investors.
Veracyte, Inc. (VCYT) sees analyst support as Guggenheim reaffirms buy rating
Guggenheim has reaffirmed its Buy rating on Veracyte, Inc. (VCYT). This indicates continued analyst support for the company.
Assessing Veracyte (VCYT) Valuation As Recent Momentum Meets An Expensive P/E Ratio
Veracyte (VCYT) has seen recent positive trading momentum, with a 90-day share price return of 21.49%, despite a mixed longer-term performance. The company's P/E ratio of 112.9x is significantly higher than industry and peer averages, suggesting it may be overvalued based on current earnings. However, a Discounted Cash Flow (DCF) model indicates the stock at $43.30 might be trading below its estimated future cash flow value, presenting a potential valuation gap.
QRG Capital Management Inc. Sells 106,926 Shares of Veracyte, Inc. $VCYT
QRG Capital Management Inc. significantly reduced its stake in Veracyte, Inc. (NASDAQ:VCYT) by 75% in the third quarter, selling 106,926 shares, leaving 35,703 shares valued at approximately $1.23 million. This move comes as company insiders, including SVP Annie McGuire and CFO Rebecca Chambers, have also been net sellers of Veracyte stock. Despite beating recent quarterly earnings and revenue estimates, analysts maintain a "Hold" consensus rating for the biotechnology company.
State of Alaska Department of Revenue Takes $1.50 Million Position in Veracyte, Inc. $VCYT
The State of Alaska Department of Revenue has acquired a new stake of 43,712 shares in Veracyte, Inc. (NASDAQ:VCYT) worth approximately $1.50 million during the third quarter, representing about 0.06% of the company. Despite positive analyst ratings and better-than-expected quarterly earnings, Veracyte saw insider selling of about 134,635 shares valued at $6.0 million in the recent quarter. The company reported EPS of $0.51 against an estimate of $0.32, with a 13.8% year-over-year revenue increase.
Sumitomo Mitsui Trust Group Inc. Sells 165,094 Shares of Veracyte, Inc. $VCYT
Sumitomo Mitsui Trust Group Inc. has reduced its stake in Veracyte, Inc. (NASDAQ:VCYT) by 10%, selling 165,094 shares and ending the quarter with 1,482,083 shares valued at approximately $50.88 million. Despite Veracyte beating its quarterly earnings and revenue expectations, its shares were down about 3.4%, and the consensus analyst rating is a "Hold" with an average price target of $46.14. The article also highlights recent significant insider selling, including shares offloaded by the CFO and CEO, totaling 134,635 shares in the last 90 days.
SG Americas Securities LLC Increases Stock Position in Veracyte, Inc. $VCYT
SG Americas Securities LLC significantly increased its stake in Veracyte, Inc. (NASDAQ:VCYT) by 124.4% in Q3, now holding 44,753 shares valued at approximately $1.54 million. Despite institutional buying, company insiders have been net sellers, with SVP Annie McGuire and CFO Rebecca Chambers reducing their holdings. Analysts currently have a "Hold" consensus rating for Veracyte with an average target price of $46.14.
Is Veracyte’s 2026 Growth Guidance And New US Launches Altering The Investment Case For Veracyte (VCYT)?
Veracyte (VCYT) has released preliminary 2025 and 2026 financial guidance, projecting significant revenue growth and stable adjusted EBITDA margins. The company plans to launch Prosigna and the TrueMRD platform in the US, aiming to diversify its cancer diagnostics portfolio beyond existing flagship tests. While this strategy could lead to a 12% upside in its fair value, investors should be aware of the execution risks associated with new product launches, payer coverage, and guideline inclusion.
Louisiana State Employees Retirement System Invests $1.24 Million in Veracyte, Inc. $VCYT
The Louisiana State Employees Retirement System has invested $1.24 million in Veracyte, Inc. by acquiring 36,200 shares. This comes amidst significant insider selling, with company officials offloading shares worth nearly $6 million in the last 90 days. Despite the insider sales, analysts maintain a "Moderate Buy" rating for Veracyte with an average price target of $46.14, following the company's recent earnings beat and revenue growth.
Veracyte stock rating reiterated at Buy by UBS on strong revenue outlook
UBS has reiterated its Buy rating on Veracyte (NASDAQ:VCYT) with a $48.00 price target, citing a strong Q4 testing revenue beat driven by higher average selling prices and favorable prior period collections. The firm maintains a positive outlook due to Veracyte's 2026 testing revenue guidance exceeding Street expectations and its projected 25% adjusted EBITDA margin. The diagnostic company's Decipher volume growth aligned with expectations, and potential new product contributions offer additional growth opportunities.
Needham reiterates Buy rating on Veracyte stock after strong Q4 preannouncement
Needham has reiterated its Buy rating and $44.00 price target on Veracyte (NASDAQ:VCYT) following the company's strong preliminary fourth-quarter 2025 results. Veracyte preannounced Q4 2025 revenue of $138-140 million, exceeding consensus, and provided optimistic 2026 guidance, reinforcing its positive financial outlook. The company also reported robust test volume growth and improved adjusted EBITDA margins, signaling strong operational performance.
Needham reiterates Buy rating on Veracyte stock after strong Q4 preannouncement
Needham has reiterated its Buy rating and $44.00 price target for Veracyte (NASDAQ:VCYT) following strong preliminary Q4 results for 2025. Veracyte preannounced Q4 2025 revenue exceeding consensus estimates and provided optimistic 2026 revenue guidance, indicating significant year-over-year growth and improved profitability. InvestingPro data highlights the company's strong financial position, with more cash than debt, healthy gross profit margins, and a low P/E ratio relative to near-term earnings growth.
Veracyte stock rating reiterated at Buy by UBS on strong revenue outlook
UBS has reiterated its Buy rating on Veracyte, Inc. (NASDAQ:VCYT) with a price target of $48.00 due to a strong Q4 testing revenue beat, significantly exceeding analyst expectations, and positive 2026 testing revenue guidance. The firm highlighted potential upside from new product contributions and stable demand for its genomic testing products. This positive outlook follows Veracyte's strong preliminary Q4 2025 revenue and significant outperformance in Q3 2025 EPS.
Veracyte stock outlook positive as Leerink reiterates Outperform rating By Investing.com
Leerink Partners has reiterated its Outperform rating and a $50.00 price target for Veracyte, Inc. (NASDAQ:VCYT), indicating a positive outlook for the diagnostic company. The company's fourth-quarter test volumes, revenue guidance, and fiscal year 2026 projections have surpassed analyst expectations, with strong growth in Decipher and Afirma test volumes. Veracyte also reported robust third-quarter 2025 earnings and increased its revenue and adjusted EBITDA margin guidance for 2025, leading to positive analyst responses and upgrades.
Veracyte stock outlook positive as Leerink reiterates Outperform rating
Leerink Partners has reiterated an Outperform rating and a $50 price target for Veracyte (NASDAQ:VCYT), indicating a positive outlook for the diagnostic company. This optimism is fueled by strong Q4 test volumes, with Decipher test volumes growing 21% year-over-year and Afirma volumes exceeding estimates, as well as revenue guidance for Q4 2025 topping analyst expectations. Additionally, Veracyte provided a robust revenue forecast for fiscal year 2026, alongside projections for maintaining strong EBITDA margins, reinforcing its financial health and growth prospects.
More cancer patients get lab answers as Veracyte test use jumps 19%
Veracyte (VCYT) announced preliminary unaudited financial results for Q4 and full-year 2025, reporting total revenue between $515 million and $517 million, a 16% increase. Testing volume grew by 19% in 2025, with Decipher volume up 27% and Afirma volume up 11%. The company expects continued growth in 2026, driven by existing tests and the planned launch of Prosigna and the TrueMRD platform in the US market.
Veracyte Announces Preliminary Fourth Quarter and Full-Year 2025 Results
Veracyte announced strong preliminary unaudited financial results for Q4 and full-year 2025, with double-digit revenue and testing volume growth. The company expects full-year revenue between $515 million and $517 million, and adjusted EBITDA margin greater than 25%. Veracyte also provided an optimistic 2026 financial outlook, projecting 10% to 13% total revenue growth and plans to launch Prosigna and TrueMRD in the U.S. market.
Morgan Stanley initiates coverage of Veracyte, Inc. (VCYT)
Morgan Stanley has initiated coverage of Veracyte, Inc. (VCYT). This indicates that the investment bank will now be providing research and analysis on the company.
Guggenheim Raises Price Target for Veracyte (VCYT) to $50.00 | V
Guggenheim has reiterated its 'Buy' rating for Veracyte (VCYT) and increased the price target by 11.11% to $50.00, reflecting continued confidence in the stock. This follows a trend of various analysts raising Veracyte's price targets recently. Veracyte is a genomic diagnostics company specializing in cancer diagnosis and treatment tests for various cancers including prostate, thyroid, breast, and bladder.
Veracyte price target raised to $50 from $45 at Guggenheim
Guggenheim analyst Subbu Nambi increased the price target for Veracyte (VCYT) to $50 from $45, while maintaining a Buy rating. This adjustment follows meetings with management teams and updated models for Diagnostic and Life Sciences Tools companies. The firm's updated models incorporate recent information from these companies.
The Truth About Veracyte Inc (VCYT): Silent Biotech Stock That Could Blow Up Your Portfolio
Veracyte Inc (VCYT) is a biotech company focused on cancer diagnostics that operates quietly while other stocks grab headlines. The article explores whether VCYT, which specializes in genomic diagnostics for early cancer detection, represents a worthwhile long-term investment or is simply another risky biotech stock. It highlights the company's technology, financial performance, and market competition, concluding that it's a "measured cop" for research-heavy portfolios due to its long-term potential despite a lack of current hype.
The Truth About Veracyte Inc (VCYT): Silent Biotech Stock That Could Blow Up Your Portfolio
This article evaluates Veracyte Inc (VCYT), a biotech company specializing in cancer diagnostics, as a potential investment. It discusses the company's business model, technology, financial aspects, and risks, comparing it to competitors. The author suggests VCYT is a "long-game position" for investors willing to research and endure volatility, rather than a quick flip or a meme stock.
